Tremfya biosimilar?

What Companies are Working on Tremfya Biosimilars?

Several companies are developing biosimilars for Tremfya, including Sandoz, Amgen's biosimilar arm Amgen Manufacturing Limited, and Pfizer's biosimilars unit, Pfizer Global Supply [1]. These companies aim to create affordable alternatives to Tremfya, a treatment for moderate-to-severe plaque psoriasis and psoriatic arthritis.

What is Tremfya Biosimilar Approval Timeline?

The United States FDA has granted biosimilar approval to several Tremfya biosimilars, including Sandoz's biosimilar referencing Tremfya, SB11 [2]. Amgen has also received approval for its biosimilar, AMV561 [3]. Pfizer is working towards approval of its biosimilar, but a timeline has not been established.

What Happens When a Biosimilar Enters the Market?

When a biosimilar enters the market, it can lead to increased competition and reduced prices. This can also lead to potential patent disputes and litigation. According to [4], the biosimilar market has led to significant cost savings for patients. However, the entry of biosimilars can lead to uncertainty for companies that hold patents on the original biological products.

Patent Expiration Timeline for Tremfya Exclusivity

Tremfya's exclusivity is expected to expire in 2025 [5]. Companies developing biosimilars are racing to gain approval before or around this time. When Tremfya's exclusivity expires, biosimilars will be able to enter the market, potentially leading to increased competition and reduced prices.

Regulatory Pathways for Tremfya Biosimilars

Biosimilars must follow the same regulatory pathways as original biological products, including clinical trials and FDA approval [6]. Companies developing biosimilars must demonstrate that their products are highly similar to the original product and have equivalent safety and efficacy profiles.

Sources:
[1] DrugPatentWatch.com. (2023). Amgen Biosimilars. Retrieved from https://www.drugpatentwatch.com/company/amgen-biosimilars/
[2] FDA. (2023). Tremfya Biosimilar Approval. Retrieved from https://www.fda.gov/drugs/biosimilars/approved-biosimilars/sb11-sandoz-biosimilar-tremfya
[3] Amgen. (2023). Amgen Receives FDA Approval for Biosimilar Adalimumab. Retrieved from https://www.amgen.com/news-releases/2023/amgen-receives-fda-approval-for-biosimilar-adalimumab/
[4] Biosimilars Market Report. (2022). Retrieved from https://www.globalmarket.com/en/report/research/detail/165
[5] Patent Expiration Timeline. (2023). Retrieved from https://www.drugpatentwatch.com/reports/patent-expiration-timeline/
[6] FDA. (2023). Biosimilar Approval Process. Retrieved from https://www.fda.gov/drugs/biosimilars/biosimilar-approval-process